AIMAIM ImmunoTech Inc.

NYSE aimimmuno.com


$ 0.40 $ 0.02 (3.95 %)    

Wednesday, 15-May-2024 15:49:31 EDT
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 0.3996
$ 0.40
$ 0.00 x 0
$ 0.00 x 0
$ 0.38 - $ 0.40
$ 0.32 - $ 0.75
172,855
na
19.76M
$ -0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-30-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 04-01-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 03-30-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 03-29-2016 12-31-2015 10-K
35 11-16-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-12-2015 03-31-2015 10-Q
38 03-19-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-08-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aim-immunotech-completes-cgmp-manufacturing-of-clinical-vials-of-ampligen

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the successfully completion of cGMP man...

 aim-immunotech-q4-eps-026-misses-015-estimate-sales-6500k-beat-4000k-estimate

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15)...

 earnings-scheduled-for-april-2-2024

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 aim-immunotech-and-3-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confid...

 aim-immunotech-launches-ceo-corner-platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides inter...

Core News & Articles

The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study with the full name "Combining...

 aim-immunotech-reports-topline-results-from-phase-2-study-evaluating-ampligen-for-treatment-of-post-covid-conditions

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety resu...

Core News & Articles

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the first subject has been enrolle...

Core News & Articles

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands 

 kellner-group-issued-statement-in-connection-with-their-efforts-to-bring-accountability-to-the-aim-immunotech-board-of-directors

On December 28, 2023, the Delaware Court of Chancery ruled in Mr. Kellner's favor that four separate advance notice bylaw p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION